OncoMatch

OncoMatch/Clinical Trials/NCT06855524

Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer

Is NCT06855524 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for malignant digestive system neoplasm.

Phase 2RecruitingMayo ClinicNCT06855524Data as of May 2026

This clinical trial tests how well fucoidan works in preventing chemotherapy-related fatigue compared to a placebo in patients with gastrointestinal (GI) or gynecological (GYN) cancer. Fatigue poses a burden in patients with malignancies undergoing systemic chemotherapy. Fucoidan is a dietary supplement made of complex sugar that contain sulfate groups attached to their sugar units (sulfated polysaccharide) which found in brown seaweed. It is thought to have anti-inflammatory, anti-viral, anti-thrombotic, anti-diabetic, and anti-tumor effects in pre-clinical models. Giving fucoidan may be effective in preventing chemotherapy-related fatigue in patients with GI or GYN.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Cholangiocarcinoma

Esophageal Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: chemotherapy and/or immunotherapy

Use of chemotherapy and/or immunotherapy ≤ 90 days prior to registration

Lab requirements

Blood counts

Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to registration)

Kidney function

Creatinine ≤ 1.5 x upper normal limit (UNL) OR calculated creatinine clearance ≥ 50 ml/min using the Cockcroft-Gault (obtained ≤ 30 days prior to registration)

Liver function

ALT and AST ≤ 1.5 x UNL; ≤ 5 x ULN for patients with liver involvement (obtained ≤ 30 days prior to registration)

Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to registration); Creatinine ≤ 1.5 x upper normal limit (UNL) OR calculated creatinine clearance ≥ 50 ml/min using the Cockcroft-Gault (obtained ≤ 30 days prior to registration); ALT and AST ≤ 1.5 x UNL; ≤ 5 x ULN for patients with liver involvement (obtained ≤ 30 days prior to registration)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Mayo Clinic in Arizona · Scottsdale, Arizona

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify